{"meta":{"query_hash":"d262bead7696","filters":{"venue":"Revista Colombiana de Gastroenterología"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/d262bead7696","api":"https://metacan.xera.ac/api/v1/cohort?venue=Revista+Colombiana+de+Gastroenterolog%C3%ADa"},"results":[{"id":"W2139767739","doi":"","title":"Tratamiento médico para enfermedad inflamatoria intestinal","year":2007,"lang":"es","type":"article","venue":"Revista Colombiana de Gastroenterología","topic":"Microscopic Colitis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ulcerative colitis; Infliximab; Inflammatory bowel disease; Adalimumab; Intensive care medicine; Crohn's disease; Disease; Inflammatory Bowel Diseases; Quality of life (healthcare); Internal medicine","score_opus":0.017344785937681215,"score_gpt":0.3077368439718635,"score_spread":0.2903920580341823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139767739","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11484931,0.75666577,0.009657263,0.026589215,0.0074306354,0.0004919099,0.00045218584,0.00081357436,0.08305015],"genre_scores_gemma":[0.5060479,0.43532407,0.012500547,0.010429203,0.010835511,0.00029639495,0.00055410416,0.00008965212,0.023922691],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962664,0.000121541976,0.00005109479,0.00005163002,0.00007610793,0.00007293044],"domain_scores_gemma":[0.99959284,0.00013042094,0.00010753712,0.000034091063,0.000055109856,0.000080113285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040317533,0.00066110305,0.001425218,0.0013769468,0.00085968786,0.00080413034,0.00044683853,0.0010424983,0.009174988],"category_scores_gemma":[0.001169195,0.00013446681,0.00074882497,0.00073742785,0.0005437233,0.00053972163,0.000646711,0.0016216055,0.0020949177],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024365191,0.0010688663,0.020012675,0.0039071045,0.00029684659,0.05786185,0.00057392713,0.00043588245,0.009333614,0.003403371,0.047839776,0.85282964],"study_design_scores_gemma":[0.0016053829,0.0041027586,0.059927627,0.0058863647,0.0011752784,0.20443378,0.0009884819,0.0013438149,0.0088374745,0.0061356197,0.70539117,0.00017222957],"about_ca_topic_score_codex":0.0021878735,"about_ca_topic_score_gemma":0.003446731,"teacher_disagreement_score":0.009174988,"about_ca_system_score_codex":0.0005750388,"about_ca_system_score_gemma":0.0008726099,"threshold_uncertainty_score":0.030693352},"labels":[],"label_agreement":null}]}